1. |
Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography[J]. J Natl Cancer Inst, 2002, 94(20):1546-1554.
|
2. |
Cutuli B, Lemanski C, Fourquet A, et al. Breast-conserving surgery with or without radiotherapy vs. mastectomy for ductal carcinoma in situ:French survey experience[J]. Br J Cancer, 2009, 100(7):1048-1054.
|
3. |
Lambert K, Patani N, Mokbel K. Ductal carcinoma in situ:recentadvances and future prospects[J]. Int J Surg Oncol, 2012. [Epub ahead of print].
|
4. |
Liberman L, Morris EA, Dershaw DD, et al. Mr imaging of the ipsilateral breast in women with percutaneously proven breast cancer[J]. AJR Am J Roentgenol, 2003, 180(4):901-910.
|
5. |
Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ:a meta-analysis[J]. Cancer, 1999, 85(3):616-628.
|
6. |
Carlson GW, Styblo TM, Lyles RH, et al. Local recurrence after skin-sparing mastectomy:tumor biology or surgical conservatism?[J]. Ann Surg Oncol, 2003, 10(2):108-112.
|
7. |
Spiegel AJ, Butler CE. Recurrence following treatment of ductal carcinoma in situ with skin-sparing mastectomy and immediate breast reconstruction[J]. Plast Reconstr Surg, 2003, 111(2):706-711.
|
8. |
Brachtel EF, Rusby JE, Michaelson JS, et al. Occult nipple involvement in breast cancer:clinicopathologic findings in 316 consecutive mastectomy specimens[J]. J Clin Oncol, 2009, 27(30):4948-4954.
|
9. |
Dillon MF, Hill AD, Quinn CM, et al. A pathologic assessment of adequate margin status in breast-conserving therapy[J]. Ann Surg Oncol, 2006, 13(3):333-339.
|
10. |
Dunne C, Burke JP, Morrow M, et al. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ[J]. J Clin Oncol, 2009, 27(10):1615-1620.
|
11. |
Ruggiero R, Procaccini E, Sanguinetti A, et al. Ductal carcinoma in situ of the breast:our experience[J]. G Chir, 2009, 30(3):121-124.
|
12. |
Revesz E, Khan SA. What are safe margins of resection forinvasive and in situ breast cancer?[J]. Oncology, 2011, 25(10):890-895.
|
13. |
Holmberg L, Garmo H, Granstrand B, et al. Absolute riskreductions for local recurrence after postoperative radiotherapyafter sector resection for ductal carcinoma in situ of the breast[J]. J Clin Oncol, 2008, 26(8):1247-1252.
|
14. |
张庆德, 王立泽, 欧阳涛, 等. 乳腺导管原位癌保乳治疗的安全性研究[J]. 中华普通外科杂志, 2011, 26(9):747-750.
|
15. |
Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS[J]. J Natl Cancer Inst, 2011, 103(6):478-488.
|
16. |
Hughes LL, Wang M, Page DL, et al. Local excision alone withoutirradiation for ductal carcinoma in situ of the breast:a trial of the Eastern Cooperative Oncology Group[J]. J Clin Oncol, 2009, 27(32):5319-5324.
|
17. |
Viani G, Stefano EJ, Afonso SL, et al. 2029 oral breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ:a meta-analysis of randomized trials[J]. Radiat Oncol, 2007, 5(4):192-193.
|
18. |
Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductalcarcinoma-in-situ:analysis of European Organization for Researchand Treatment of Cancer Trial 10853[J]. J Clin Oncol, 2001, 19(8):2263-2271.
|
19. |
Silverstein MJ, Buchanan C. Ductal carcinoma in situ:USC/van nuys prognostic index and the impact of margin status[J]. Breast, 2003, 12(6):457-471.
|
20. |
Motwani SB, Goyal S, Moran MS, et al. Ductal carcinoma in situ treated with breast-conserving surgery and radiotherapy:a comparison with ECOG study 5194[J]. Cancer, 2011, 117(6):1156-1162.
|
21. |
Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ:long-term results from the UK/ANZ DCIS trial[J]. Lancet Oncol, 2011, 12(1):21-29.
|
22. |
刘志艳, 刘维帅, 王平. 乳腺导管原位癌术后辅助放疗[J]. 国际肿瘤学杂志, 2012, 39(12):928-931.
|
23. |
Silverstein MJ. An argument against routine use of radiotherapy for ductal carcinoma in situ[J]. Oncology, 2003, 17(11):1511-1533.
|
24. |
Wapnir I. Long-term outcomes after invasive breast tumor recurrence (IBTR) in women with DCIS in NSABP B-17 and B-24[J]. J Clin Oncol, 2007, 25(520):95-102.
|
25. |
Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ:an update of the National Surgical Adjuvant Breast and Bowel Project experience[J]. Semin Oncol, 2001, 28(4):400-418.
|
26. |
Morrow M, Strom EA, Bassett LW, et al. Standard for the management of ductal carcinoma in-situ of the breast (DCIS)[J]. CA Cancer J Clin, 2002, 52(5):256-276.
|
27. |
Yen TW, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ:a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ[J]. J Am Coll Surg, 2005, 200(4):516-526.
|
28. |
Dillon MF, Mcdermott EW, Quinn CM, et al. Predictors of invasive disease in breast cancer when core biopsy demonstrates DCIS only[J]. J Surg Oncol, 2006, 93(7):559-563.
|
29. |
Intra M, Rotmensz N, Veronesi P, et al. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast:the experience of the European institute of oncology on 854 patientsin 10 years[J]. Ann Surg, 2008, 247(2):315-319.
|
30. |
Tada K, Ogiya A, Kimura K, et al. Ductal carcinoma in situ and sentinel lymph node metastasis in breast cancer[J]. World J Surg Oncol, 2010, 8:6.
|
31. |
Shapiro-Wright HM, Julian TB. Sentinel lymph node biopsy and management of the axilla in ductal carcinoma in situ[J]. J Natl Cancer Inst Monogr, 2010, 2010(41):145-149.
|
32. |
Veronesi P, Intra M, Vento AR, et al. Sentinel lymph node biopsyfor localised ductal carcinoma in situ?[J]. Breast, 2005, 14(6):520-522.
|
33. |
Julian TB, Land SR, Fourchotte V, et al. Is sentinel node biopsy necessary in conservatively treated DCIS?[J]. Ann Surg Oncol, 2007, 14(8):2202-2208.
|
34. |
Sakr R, Antoine M, Barranger E, et al. Value of sentinel lymph node biopsy in breast ductal carcinoma in situ upstaged to invasive carcinoma[J]. Breast J, 2008, 14(1):55-60.
|
35. |
Morrow M, Lantz P, Janz N, et al. Patterns and correlates of breast reconstruction:results of a population based study[J]. J Clin Oncol, 2004, 22(14 Suppl):557.
|
36. |
Solin LJ, Fourquet A, Vicini FA, et al. Long-term outcome after breast-conservation treatment with radiation for mammographicallydetected ductal carcinoma in situ of the breast[J]. Cancer, 2005,.
|
37. |
Lawrence JS, Fourquet A, Vicini FA, et al. Salvage treatment for local or local-regional recurrence after initial breast conservationtreatment with radiation for ductal carcinoma in situ[J]. Eur J Cancer, 2005, 41(12):1715-1723.
|
38. |
Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of protocol B-17:intraductal carcinoma[J]. Cancer, 1999, 86(3):429-438.
|
39. |
廖宁, 钱学珂. 导管原位癌行区段切除术后同侧浸润性癌复发的长期随访结果:NSABP B-17和B-24两项研究的联合分析[J]. 循证医学, 2011, 11(3):145-147.
|
40. |
Head JF, Elliott RL. Stereotactic radiofrequency ablation:a minimally invasive technique for nonpalpable breast cancer in postmenopausal patients[J]. Cancer Epidemiol, 2009, 33(3-4):300-305.
|
41. |
Wen HC, Avivar-Valderas A, Sosa MS, et al. p38α signaling induces anoikis and lumen formation during mammary morphogenesis[J]. Sci Signal, 2011, 4(174):ra34.
|
42. |
Chen L, Mayer JA, Krisko TI, et al. Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells[J]. Cancer Res, 2009, 69(23):8853-8861.
|
43. |
(6):1137-1146.
|